Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477750 · ClinicalTrials.gov registry record · Phase 1
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00477750: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00477750 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00477750, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as melphalan, prednisone, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of melphalan and lenalidomide when given together with prednisone and to see how well they work in treating patients with newly diagnosed multiple myeloma.
Interventions
- DRUG prednisone
- DRUG lenalidomide
- DRUG melphalan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2005-06 |
| Est. Completion | 2013-08-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477750
The ClinicalTrials.gov registry entry for NCT00477750 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which prednisone is the first listed.
NCT00477750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00477750 about?
NCT00477750 is a clinical study titled "Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma". RATIONALE: Drugs used in chemotherapy, such as melphalan, prednisone, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE:...
What is the current status of trial NCT00477750?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2005-06. Estimated completion is 2013-08-05.
What interventions are being tested in trial NCT00477750?
The interventions under investigation include: prednisone (DRUG), lenalidomide (DRUG), melphalan (DRUG).
Who is sponsoring clinical trial NCT00477750?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.